HRP20080099T3 - Imidazole derivatives used as tafia inhibitors - Google Patents
Imidazole derivatives used as tafia inhibitorsInfo
- Publication number
- HRP20080099T3 HRP20080099T3 HR20080099T HRP20080099T HRP20080099T3 HR P20080099 T3 HRP20080099 T3 HR P20080099T3 HR 20080099 T HR20080099 T HR 20080099T HR P20080099 T HRP20080099 T HR P20080099T HR P20080099 T3 HRP20080099 T3 HR P20080099T3
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- cycloalkyl
- formula
- unsubstituted
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Spoj formule Ia, i(li) svi stereoizomerni oblici spoja formule Ia i(li) smjesa tih oblika u bilo kojem odnosu, i(li) fiziološki prihvatljiva sol spoja formule Ia, gdjeU je atom vodika, X je ostatak formule II -(A1)m-A2 (II) gdjem je cijeli broj 1, A1 je -CH2-,A2 je aminopiridil, gdje aminopiridil nesupstituiran ili je međusobno neovisno jednom, dva ili tri puta supstituiran s halogenom ili -CH3,Y je -(C3-C8)-cikloalkil, gdje je cikloalkil nesupstituiran ili međusobno neovisno jednom, dva ili tri puta supstituiran s R1, gdje R1 jea) fenil, gdje je fenil nesupstituiran ili jednom, dva ili tri puta međusobno neovisno supstituiran s -(C1-C4)-alkilom, b) triazolil ili piridinil, c) -(C1-C4)-alkil, d) -(C3-C6)-cikloalkil, e) -CF3,f) -O-CF3,g) fluor ilih) klor, iZ je 1) atom vodika, 2) -(C1-C6)-alkil, 3) -(C1-C6)-alkil-OH, 4) -(C0-C4)-alkil-(C3-C6)-cikloalkil ili5) -(C1-C10)-alkil-O-C(O)-O-(C3-C6)-cikloalkil. Patent sadrži još 6 patentnih zahtjeva.A compound of formula Ia, and (li) all stereoisomeric forms of a compound of formula Ia and (li) a mixture of these forms in any ratio, and (li) a physiologically acceptable salt of a compound of formula Ia, wherein U is a hydrogen atom, X is a residue of formula II - (A1 ) m-A2 (II) wherein the integer is 1, A1 is -CH2-, A2 is aminopyridyl, wherein aminopyridyl is unsubstituted or is independently one, two or three times substituted with halogen or -CH3, Y is - (C3-C8 ) -cycloalkyl, wherein cycloalkyl is unsubstituted or independently one, two or three times substituted with R1, wherein R1 is aa) phenyl, wherein phenyl is unsubstituted or once, two or three times independently substituted with - (C1-C4) -alkyl , b) triazolyl or pyridinyl, c) - (C1-C4) -alkyl, d) - (C3-C6) -cycloalkyl, e) -CF3, f) -O-CF3, g) fluoro or chlorine, iZ is 1) hydrogen atom, 2) - (C1-C6) -alkyl, 3) - (C1-C6) -alkyl-OH, 4) - (C0-C4) -alkyl- (C3-C6) -cycloalkyl or5) - (C1-C10) -alkyl-OC (O) -O- (C3-C6) -cycloalkyl. The patent contains 6 more patent claims.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004020186A DE102004020186A1 (en) | 2004-04-22 | 2004-04-22 | Heterocyclyl acetic acids as inhibitors of TAFla |
| PCT/EP2005/003630 WO2005105781A1 (en) | 2004-04-22 | 2005-04-07 | Imidazole derivatives used as tafia inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20080099T3 true HRP20080099T3 (en) | 2008-03-31 |
Family
ID=34964308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20080099T HRP20080099T3 (en) | 2004-04-22 | 2005-04-07 | Imidazole derivatives used as tafia inhibitors |
Country Status (34)
| Country | Link |
|---|---|
| EP (2) | EP1740569B1 (en) |
| JP (1) | JP4939401B2 (en) |
| KR (1) | KR101162047B1 (en) |
| CN (1) | CN100572376C (en) |
| AR (1) | AR053302A1 (en) |
| AT (2) | ATE386737T1 (en) |
| AU (1) | AU2005238144B2 (en) |
| BR (1) | BRPI0510159A (en) |
| CA (1) | CA2563401C (en) |
| CR (1) | CR8650A (en) |
| CY (1) | CY1108087T1 (en) |
| DE (2) | DE102004020186A1 (en) |
| DK (1) | DK1740569T3 (en) |
| EC (1) | ECSP066941A (en) |
| ES (1) | ES2299026T3 (en) |
| HR (1) | HRP20080099T3 (en) |
| IL (1) | IL178672A (en) |
| MA (1) | MA28543B1 (en) |
| MY (1) | MY140903A (en) |
| NI (1) | NI200600217A (en) |
| NO (1) | NO20065320L (en) |
| NZ (1) | NZ550757A (en) |
| PE (1) | PE20060172A1 (en) |
| PL (1) | PL1740569T3 (en) |
| PT (1) | PT1740569E (en) |
| RS (1) | RS50553B (en) |
| RU (1) | RU2375356C2 (en) |
| SI (1) | SI1740569T1 (en) |
| TN (1) | TNSN06341A1 (en) |
| TW (1) | TWI359016B (en) |
| UA (1) | UA87306C2 (en) |
| UY (1) | UY28868A1 (en) |
| WO (1) | WO2005105781A1 (en) |
| ZA (1) | ZA200607668B (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007327959B2 (en) * | 2006-12-06 | 2013-08-01 | Sanofi-Aventis | Urea and sulfamide derivatives as tafia inhibitors |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| EP2142538B1 (en) * | 2007-02-13 | 2011-10-26 | Schering Corporation | Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists |
| KR20100033419A (en) | 2007-07-19 | 2010-03-29 | 메타볼렉스, 인코포레이티드 | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders |
| EP2262783A2 (en) * | 2008-02-21 | 2010-12-22 | Sanofi-Aventis | Covalently binding imaging probes |
| DK2300462T3 (en) | 2008-06-06 | 2014-08-18 | Sanofi Sa | MACROCYCLIC CARBAMIDE AND SULFAMIDE DERIVATIVES AS TAFIA INHIBITORS |
| NZ592764A (en) | 2008-10-29 | 2012-08-31 | Taisho Pharmaceutical Co Ltd | Compound having tafia inhibitory activity |
| JP5706397B2 (en) * | 2009-05-15 | 2015-04-22 | サノフイ | Method for producing compound useful as inhibitor of TAFIa |
| FR2947266B1 (en) * | 2009-06-26 | 2011-06-17 | Servier Lab | NOVEL 2-MERCAPTOCYCLOPENTANECARBOXYLIC ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
| CN102666553B (en) | 2009-10-01 | 2015-05-06 | 赛马拜制药公司 | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
| SI2548871T1 (en) | 2010-03-18 | 2017-10-30 | Daiichi Sankyo Company, Limited | Cycloalkyl-substituted imidazole derivative |
| KR20130006620A (en) | 2010-03-18 | 2013-01-17 | 다이이찌 산쿄 가부시키가이샤 | Cyclopropanecarboxylic acid derivative |
| CN103201269A (en) | 2010-11-11 | 2013-07-10 | 赛诺菲 | Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives |
| US9102657B2 (en) * | 2011-11-25 | 2015-08-11 | Sanofi | Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid |
| WO2013076177A1 (en) | 2011-11-25 | 2013-05-30 | Sanofi | Salt of (r)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1h-imidazol-4-yl) ethyl propionate |
| US9145385B2 (en) | 2011-11-25 | 2015-09-29 | Sanofi | Crystalline salts of R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexy1-1H-imidazol-4-yl)-propionic acid |
| EP3184095A1 (en) | 2013-05-23 | 2017-06-28 | IP Gesellschaft für Management mbH | Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide |
| WO2014198620A1 (en) * | 2013-06-10 | 2014-12-18 | Sanofi | Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals |
| JPWO2017170460A1 (en) | 2016-03-29 | 2019-02-07 | 第一三共株式会社 | Inflammatory bowel disease treatment |
| CN109862896A (en) | 2016-08-03 | 2019-06-07 | 西玛贝医药公司 | Oxymethylene aryl compounds for use in the treatment of inflammatory gastrointestinal diseases or gastrointestinal disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20012338A3 (en) * | 1998-12-24 | 2001-12-12 | Fujisawa Pharmaceutical Co., Ltd. | Imidazole compounds |
| WO2003013526A1 (en) * | 2001-08-08 | 2003-02-20 | Merck & Co. Inc. | Anticoagulant compounds |
| EP1467732A1 (en) | 2002-01-22 | 2004-10-20 | Pfizer Limited | 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
-
2004
- 2004-04-22 DE DE102004020186A patent/DE102004020186A1/en not_active Withdrawn
-
2005
- 2005-04-06 PE PE2005000382A patent/PE20060172A1/en not_active Application Discontinuation
- 2005-04-07 SI SI200530185T patent/SI1740569T1/en unknown
- 2005-04-07 KR KR1020067021881A patent/KR101162047B1/en not_active Expired - Fee Related
- 2005-04-07 ES ES05731221T patent/ES2299026T3/en not_active Expired - Lifetime
- 2005-04-07 NZ NZ550757A patent/NZ550757A/en not_active IP Right Cessation
- 2005-04-07 AT AT05731221T patent/ATE386737T1/en active
- 2005-04-07 HR HR20080099T patent/HRP20080099T3/en unknown
- 2005-04-07 RS RSP-2008/0107A patent/RS50553B/en unknown
- 2005-04-07 CN CNB2005800115593A patent/CN100572376C/en not_active Expired - Fee Related
- 2005-04-07 PT PT05731221T patent/PT1740569E/en unknown
- 2005-04-07 BR BRPI0510159-0A patent/BRPI0510159A/en not_active Application Discontinuation
- 2005-04-07 CA CA2563401A patent/CA2563401C/en not_active Expired - Fee Related
- 2005-04-07 JP JP2007508756A patent/JP4939401B2/en not_active Expired - Fee Related
- 2005-04-07 DK DK05731221T patent/DK1740569T3/en active
- 2005-04-07 DE DE502005002927T patent/DE502005002927D1/en not_active Expired - Lifetime
- 2005-04-07 PL PL05731221T patent/PL1740569T3/en unknown
- 2005-04-07 EP EP05731221A patent/EP1740569B1/en not_active Expired - Lifetime
- 2005-04-07 RU RU2006141246/04A patent/RU2375356C2/en not_active IP Right Cessation
- 2005-04-07 AU AU2005238144A patent/AU2005238144B2/en not_active Ceased
- 2005-04-07 WO PCT/EP2005/003630 patent/WO2005105781A1/en not_active Ceased
- 2005-04-07 AT AT07017340T patent/ATE523505T1/en active
- 2005-04-07 EP EP07017340A patent/EP1864979B1/en not_active Expired - Lifetime
- 2005-04-20 MY MYPI20051748A patent/MY140903A/en unknown
- 2005-04-20 TW TW094112493A patent/TWI359016B/en not_active IP Right Cessation
- 2005-04-20 AR ARP050101556A patent/AR053302A1/en not_active Application Discontinuation
- 2005-04-22 UY UY28868A patent/UY28868A1/en unknown
- 2005-07-04 UA UAA200612254A patent/UA87306C2/en unknown
-
2006
- 2006-09-13 ZA ZA200607668A patent/ZA200607668B/en unknown
- 2006-09-20 NI NI200600217A patent/NI200600217A/en unknown
- 2006-09-22 CR CR8650A patent/CR8650A/en unknown
- 2006-10-17 IL IL178672A patent/IL178672A/en not_active IP Right Cessation
- 2006-10-19 MA MA29399A patent/MA28543B1/en unknown
- 2006-10-20 TN TNP2006000341A patent/TNSN06341A1/en unknown
- 2006-10-20 EC EC2006006941A patent/ECSP066941A/en unknown
- 2006-11-20 NO NO20065320A patent/NO20065320L/en not_active Application Discontinuation
-
2008
- 2008-05-12 CY CY20081100491T patent/CY1108087T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20080099T3 (en) | Imidazole derivatives used as tafia inhibitors | |
| TW200833324A (en) | Sulfonamide derivatives | |
| MY138941A (en) | Aryl-pyridine derivatives | |
| MX2010007977A (en) | Azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof. | |
| MX2009002229A (en) | Benzotriazole kinase modulators. | |
| MXPA05010760A (en) | Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists. | |
| CO6241102A2 (en) | FORMULATIONS CONTAINING TRIAZINONES AND IRON | |
| MY144209A (en) | Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors | |
| JP2010535870A5 (en) | ||
| TW200738655A (en) | Novel bicyclic sulfonamide derivatives | |
| EA200970161A1 (en) | DERIVATIVES 1 - (- D-GLYCOPHRANOSYL) -3- (4-CYCLOPROPYLPHENYLMETHYL) -4-HALOGENOINDOL AND THEIR APPLICATION AS SGLT INHIBITORS | |
| MXPA05011411A (en) | Substituted 1,4-diazepines and uses thereof. | |
| MY144461A (en) | Cinnamoyl-piperazine derivatives and their use as par-1 antagonists | |
| IL164511A0 (en) | Heterocyclic compounds | |
| UA102310C2 (en) | Heterocyclic sufonamides, use thereof and pharmaceuticsl compositions | |
| MX2009010218A (en) | Aza-pyridopyrimidinone derivatives. | |
| ATE477256T1 (en) | THIENYL COMPOUNDS | |
| DE602006021539D1 (en) | Morpholine als 5ht2c-agonisten | |
| TW200745063A (en) | Triazolone derivatives | |
| NO20044767L (en) | Pharmaceutical formulation with modified release | |
| PL1685142T3 (en) | Phosphinic acid derivatives, beta-secretase inhibitors for the treatment of alzheimer's disease | |
| NO20070089L (en) | DPP-IV inhibitors | |
| MY139522A (en) | New alkyl-pyridines as 11-beta inhibitors for diabetes | |
| MX2009003169A (en) | Sulfonamide derivatives. | |
| IL180428A0 (en) | Novel flame-retardant polystyrenes |